SE8700466D0 - Vaccines against melanoma - Google Patents

Vaccines against melanoma

Info

Publication number
SE8700466D0
SE8700466D0 SE8700466A SE8700466A SE8700466D0 SE 8700466 D0 SE8700466 D0 SE 8700466D0 SE 8700466 A SE8700466 A SE 8700466A SE 8700466 A SE8700466 A SE 8700466A SE 8700466 D0 SE8700466 D0 SE 8700466D0
Authority
SE
Sweden
Prior art keywords
peptides
proteins
vaccine formulations
vaccines against
melanoma
Prior art date
Application number
SE8700466A
Other languages
English (en)
Other versions
SE506024C2 (sv
SE8700466L (sv
Inventor
J P Brown
C D Estin
G D Plowman
T M Rose
K E Hellstrom
I Hellstrom
A F Purchio
S-L Hu
S Pennathur
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26676698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE8700466(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/007,230 external-priority patent/US5262177A/en
Application filed by Oncogen filed Critical Oncogen
Publication of SE8700466D0 publication Critical patent/SE8700466D0/sv
Publication of SE8700466L publication Critical patent/SE8700466L/sv
Publication of SE506024C2 publication Critical patent/SE506024C2/sv

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/5743Specifically defined cancers of skin, e.g. melanoma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00119Melanoma antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79Transferrins, e.g. lactoferrins, ovotransferrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SE8700466A 1986-02-07 1987-02-06 Melanomassocierat P97 antigen och immunogen komposition SE506024C2 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82731386A 1986-02-07 1986-02-07
US07/007,230 US5262177A (en) 1986-02-07 1987-01-27 Recombinant viruses encoding the human melanoma-associated antigen

Publications (3)

Publication Number Publication Date
SE8700466D0 true SE8700466D0 (sv) 1987-02-06
SE8700466L SE8700466L (sv) 1987-08-08
SE506024C2 SE506024C2 (sv) 1997-11-03

Family

ID=26676698

Family Applications (2)

Application Number Title Priority Date Filing Date
SE8700466A SE506024C2 (sv) 1986-02-07 1987-02-06 Melanomassocierat P97 antigen och immunogen komposition
SE9202934A SE9202934D0 (sv) 1986-02-07 1992-10-07 Vacciner mot melanom

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE9202934A SE9202934D0 (sv) 1986-02-07 1992-10-07 Vacciner mot melanom

Country Status (18)

Country Link
JP (3) JP2664673B2 (sv)
BE (1) BE1000175A3 (sv)
CH (1) CH675424A5 (sv)
DE (1) DE3703702C2 (sv)
DK (1) DK63287A (sv)
ES (2) ES2012815A6 (sv)
FI (1) FI94836C (sv)
GR (1) GR870195B (sv)
HU (1) HU209144B (sv)
IE (1) IE59597B1 (sv)
IT (1) IT1222359B (sv)
MX (1) MX9203574A (sv)
NL (1) NL8700285A (sv)
NO (1) NO178931C (sv)
NZ (1) NZ219192A (sv)
OA (1) OA08478A (sv)
PT (1) PT84255B (sv)
SE (2) SE506024C2 (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19821925A1 (de) * 1998-05-15 1999-11-18 Roehnisch Tim Verfahren zur Herstellung einer Zusammensetzung zur Induktion einer tumorspezifischen Immunantwort, sowie Verwendung der Zusammensetzung zur Behandlung von Neoplasien
JP4414023B2 (ja) * 1999-08-05 2010-02-10 オリエンタル酵母工業株式会社 関節炎関連メラノトランスフェリンの測定方法および試薬
JP4708027B2 (ja) * 2002-10-01 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 抗癌組成物および抗感染疾患組成物ならびにこれらを使用する方法
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer

Also Published As

Publication number Publication date
IT8719291A0 (it) 1987-02-06
BE1000175A3 (fr) 1988-07-12
JPH08280390A (ja) 1996-10-29
OA08478A (fr) 1988-07-29
GR870195B (en) 1987-06-10
PT84255A (en) 1987-03-01
JP2664673B2 (ja) 1997-10-15
HU209144B (en) 1994-03-28
NL8700285A (nl) 1987-09-01
JPH09135692A (ja) 1997-05-27
NO870475L (no) 1987-08-10
ES2017258A6 (es) 1991-01-16
IE59597B1 (en) 1994-03-09
FI870501A (sv) 1987-08-08
HUT43107A (en) 1987-09-28
PT84255B (pt) 1989-11-30
SE506024C2 (sv) 1997-11-03
SE8700466L (sv) 1987-08-08
DE3703702C2 (de) 1997-07-10
NO178931B (no) 1996-03-25
DK63287D0 (da) 1987-02-06
IE870319L (en) 1987-08-07
DE3703702A1 (de) 1988-02-18
IT1222359B (it) 1990-09-05
MX9203574A (es) 1992-07-01
FI94836C (sv) 1995-11-10
FI870501A0 (sv) 1987-02-06
NZ219192A (en) 1991-10-25
NO178931C (no) 1996-07-03
JPS62294698A (ja) 1987-12-22
FI94836B (sv) 1995-07-31
ES2012815A6 (es) 1990-04-16
SE9202934D0 (sv) 1992-10-07
DK63287A (da) 1987-08-08
CH675424A5 (en) 1990-09-28
NO870475D0 (no) 1987-02-06

Similar Documents

Publication Publication Date Title
ATE97164T1 (de) Rekombinantes vaccinia-virus mva.
DK0584348T3 (da) Genetisk vaccine mod immundefektvirusser
ATE258188T1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
ATE229978T1 (de) Helicobacter proteine und impstoffe
NO863803L (no) Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids).
FI102382B1 (sv) Expressionssystem för kimeriska glykoproteiner innehållande immunogeniska fragment av glykoproteiner av människans respiratory syncytial -virus
HUP9902438A2 (hu) Parapoxvírus vektorok
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
DE69936337D1 (de) Verfahren zur entwicklung von einem hiv impfstoff
DE3689622D1 (de) Impfstoffe gegen menschliche respiratorische viren.
DK482788A (da) Vacciner mod og diagnostiske bestemmelser af haemophilus influenzae
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
AR009365A1 (es) Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno
SE8700466D0 (sv) Vaccines against melanoma
KR900701291A (ko) 혈호균속 인플루엔자용 백신과 진단검사법
NZ213303A (en) Plasmodium protein, dna sequence and vaccine
DE69428984D1 (de) Stimulierung der immunantwort durch virales protein
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
MX9301736A (es) Vacuna de bacterina-toxoide de pasteurella haemolytica tipo a-1.
RU92004487A (ru) Днк, полипептид, вакцина, вектор, микроорганизм, клетка насекомого, реагент, способы лечения и профилактики, способ обнаружения антигенов
Pauksen B and T cell immunity after bone marrow transplantation: Studies with special reference to measles immunity.

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8700466-9

Format of ref document f/p: F